S13 Ep21: T-DXd's Efficacy Stands Strong and Supports IHC Testing in HER2-Mutated NSCLC: With Misako Nagasaka, MD, PhD

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr Nagasaka discusses the evolving use of T-DXd for HER2-mutated NSCLC in light of the emergence of investigational agents in this setting.